pharmaphorum

MAY 9, 2022

SparkRx is designed to decrease depression in individuals aged 13 to 22 by providing a multi-week programme based on cognitive behavioural therapy (CBT) and behavioural activation protocols. “In In primary care, there are guidelines to screening for behavioural health concerns like depression annually. Designing the app.

Behavioural Health 135

Behavioural Health Production Life Science Development 135

pharmaphorum

DECEMBER 22, 2021

The 2022 intake companies are: Carium , which operates a telehealth platform – delivered via a patient app – that provides individualised care to patients from participating healthcare systems and links to a range of wearable devices; Clear Bill of Health (CBOH), which has developed as a COVID-19 vaccination and testing status facilitation tool; Culture (..)

Behavioural Health 122

Behavioural Health Life Science Vaccine Vaccination 122

pharmaphorum

JANUARY 27, 2022

I observed that my colleagues who were working to develop and validate various clinical applications of virtual reality technology had no venue to publish their work in a way that would reach other scientists grappling with the same issues and constraints,” Greenleaf said. . To learn more about the IVRHA conference, click here.

Production 142

Production Development Behavioural Health Research 142

pharmaphorum

JANUARY 26, 2021

There is an opportunity to address this at scale with digital tools and techniques, and expand support into just about any therapeutic area through the holistic integration of mental and behavioural health solutions that improve patient care. Services to manage and make sense of the health data explosion.

Clinical Trials 141

Clinical Trials Clinical Trials Sales Life Science 141

pharmaphorum

APRIL 25, 2022

Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of business development, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . Gani started BehaVR in 2016 to create DTx for mental and behavioural health.

Behavioural Health 105

Behavioural Health Production Clinical Trials Clinical Trials 105

pharmaphorum

MARCH 21, 2022

In 2021, the behavioural health company and Sumitomo Dainippon Pharma Co. in Japan announced their partnership to develop and commercialise prescription digital therapeutics and general wellness products to treat social anxiety disorder, generalised anxiety, and major depressive disorder. About the author .

Behavioural Health 98

Behavioural Health Pharma Companies Life Science FDA Approval 98